Navigation Links
Predicting ovarian cancer survival through tumor-attacking immune cells
Date:12/4/2013

SEATTLE One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult until now.

Scientists at Fred Hutchinson Cancer Research Center have developed a new method for counting a special class of cancer-fighting cells called tumor-infiltrating T lymphocytes, or TILs reliably, quickly and cheaply in patients with early stage and advanced ovarian cancer. They describe their findings online Dec. 4 in Science Translational Medicine.

Such technology, a DNA-amplification technique, has the potential to predict treatment response, cancer recurrence and disease-free survival earlier and more effectively than any current method, according to lead researcher and cancer geneticist Jason H. Bielas, Ph.D., an associate member of the Human Biology and Public Health Sciences divisions at Fred Hutch.

"Our experiments demonstrate an association between higher TIL counts and improved survival among women with ovarian cancer, and are consistent with prior observations that the immune response against ovarian cancer is a meaningful and independent prognostic factor," said Bielas, who was also the paper's corresponding and senior author.

"While variations in the measurement and characterization of TILs have limited their clinical utility as biomarkers of survival, our results highlight the significant translational potential of a robust, standardized, DNA-based assay to assess TILs in a variety of cancer types, including ovarian," he said.

Fred Hutch researchers developed the digital assay to count TILs, determine their frequency and develop a grouping system to determine their "clonality," a measure of the tumor's T-cell population.

In developing the test, Bielas and his team leveraged a technology co-created by first author Harlan S. Robins, Ph.D., a computational biologist and associate member of the Public Health Sciences and Human Biology divisions at Fred Hutch. They devised a way to easily screen T cells by capturing the genetic information of unique proteins these cells carry on their surface. Fred Hutch licensed the technology to Adaptive Biotechnologies, a company Robins co-founded.

In the present study, Robins, Bielas and colleagues tested this novel technique, called "QuanTILfy," on tumor samples from 30 ovarian cancer patients with known survival outcomes ranging from one to 22 months. They looked at the levels of TILs in their tumors and compared those levels to the women's survival. They found that higher TIL numbers correlated with better survival. For example, the percentage of TILs was approximately threefold higher on average for patients with a survival rate of more than five years as compared to patients with a survival rate of less than two years.

"Now that we have the sensitivity and ability to reproducibly count TILs in tumors, we may be able to stratify and more effectively treat patients based on tumor TIL count," Bielas said.


'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Study examines BI-RADS and MRI in predicting breast cancer
2. Predicting post-traumatic stress disorder before it happens
3. A new model for predicting recovery after spinal cord injury
4. Study uncovers simple way of predicting severe pain following breast cancer surgery
5. Researchers develop non-invasive technique for predicting patients response to chemotherapy
6. Predicting, preventing, and controlling pandemics: Making the case for a strategic action plan
7. Valuable tool for predicting pain genes in people
8. Combining diagnostic tests more accurate at predicting Alzheimers
9. Predicting risk of arrhythmias and sudden cardiac death: Theres a computer model for that
10. Predicting hotspots for future flu outbreaks
11. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... Immunotherapy has emerged ... number of cancers and is touted to be the next revolution in our fight ... has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... SAN FRANCISCO , March 29, 2017 /PRNewswire/ ... an option agreement with Bionure Farma, S.L. for ... BN201 and to BN119 in the field of ... million plus sales-based royalties. The agreement provides ... stage assets with a differentiated product profile. Under ...
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
Breaking Medicine Technology: